Laurie Barclay, MD Aug. 28, 2002
After percutaneous coronary intervention (PCI), six months of homocysteine-lowering therapy with vitamins B6, B12, and folic acid reduced the composite of death, nonfatal myocardial infarction (MI), and need for repeat revascularization at six months and one year, according to the results of a controlled trial reported in the Aug. 28 issue of The Journal of the American Medical Association. Further research should help determine optimal doses and the true mechanism of cardiac benefit.
“Plasma homocysteine level has been recognized as an important cardiovascular risk factor that predicts adverse cardiac events in patients with established coronary atherosclerosis and influences restenosis rate after PCI,” write Guido Schnyder, MD, from the University of California, San Diego, and colleagues.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!